

Haematologica
HAEMATOL/2019/235705
Version 3

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)

Francesca R Mauro, Stefano Molica, Stefano Soddu, Fiorella Ilariucci, Marta Coscia, Francesco Zaja, Emanuele Angelucci, Francesca Re, Anna Marina Liberati, Alessandra Tedeschi, Gianluigi Reda, Daniela Pietrasanta, Alessandro Gozzetti, Roberta Battistini, Giovanni Del Poeta, Caterina Musolino, Mauro Nanni, Alfonso Piciocchi, Marco Vignetti, Antonino Neri, Francesco Albano, Antonio Cuneo, Ilaria Del Giudice, Irene Della Starza, Maria Stefania De Propriis, Sara Raponi, Anna R Guarini, and Robin Foà

Disclosures: Novartis provided ofatumumab and financial support to GIMEMA for the management of this study. This study received a financial support by AIRC (Associazione Italiana per la Ricerca sul Cancro) Special Program Molecular Clinical Oncology, 5x1000, No. 10007, Milan, Italy. Competing Interests of Authors FRM: consulting fees and grants from Janssen, Abbvie, Gilead, Roche, Shire. RF: consulting fees, from Janssen, Abbvie, Roche, Celgene, Amgen, Novartis, Incyte, Sandoz. SM: consulting fees and grants from Janssen, Abbvie, Roche. Gilead. MC: consulting fees and grants from Janssen, Abbvie, Gilead. FZ: consulting fees and grants from Janssen, Abbvie, Gilead, Roche, Novartis, Amgen, Celgene, BMS, Sandoz. EA: consulting fees and grants from Novartis, Abbvie, Amgen, Celgene, BlueBirdBio, Vertex Pharma inc. and CRISPR CAS 9 Therapeutics. AML: consulting fees and grants from Janssen, Abbvie, Roche, Amgen, Celgene, BMS, Takeda, Servier, Incyte. AT: consulting fees and grants from Janssen, Abbvie, Gilead, Roche. GR: consulting fees and grants from Janssen, Abbvie, Gilead. AG: consulting fees and grants from Janssen, Abbvie, Amgen, Celgene. GDP: consulting fees and grants from Janssen, Abbvie, Roche. AC: consulting fees and grants from Janssen, Abbvie, Gilead, Roche. The remaining authors did not declare conflict of interest.

Contributions: FRM: involved in study design, patient enrollment and management, data collection and analysis, manuscript writing. SM, IF, MC, FZ, EA, FR, AML, AT, GR, AB, AG, RB, GDP, CM: involved in patient enrollment and management, data collection, and manuscript reviewing. MN, AN, FA, AC, IDG, IDS. MSDP, SR, ARG: performed laboratory-based research and manuscript reviewing. SS, AP: involved in statistical analysis and manuscript review. MV: involved in the study organization and manuscript review. RF: involved in study design, data analysis, manuscript writing